Risks of female genital tract related cancers (gynecological cancers) or breast cancer in women with and without chronic kidney disease: A population-based cohort study in Taiwan
- PMID: 29561423
- PMCID: PMC5895333
- DOI: 10.1097/MD.0000000000010157
Risks of female genital tract related cancers (gynecological cancers) or breast cancer in women with and without chronic kidney disease: A population-based cohort study in Taiwan
Abstract
This article aims to test the hypothesis that the risk of female genital tract related cancer (gynecological cancer: GC) or breast cancer (BC) of women with chronic kidney disease (CKD) might be different from that of those women without CKD.A nationwide 17-year historic cohort study using the National Health Insurance Research Database (NHIRD) of Taiwan and the Registry for Catastrophic Illness Patients was conducted. A total of 3045 women with a diagnosis of CKD from 1996 to 2013 and 3045 multivariable-matched controls (1:1) were selected. We used Cox regression, and computed hazard ratios (HRs) with 95% confidence intervals (95% CIs) to determine the risk of GC or BC in women.The GC incidence rates (IRs, per 10,000 person-years) of the CKD and non-CKD women were 11.02 and 19.09, respectively, contributing to a significantly decreased risk of GCs (crude HR 0.57, 95% CI 0.39-0.81; adjusted HR 0.44, 95% CI 0.30-0.65) in the CKD women. The GC IR was relatively constant in the CKD women among the different age categories (IR ranged from 8.10 to 12.29). On contrast, the non-CKD women had a progressive and continuous increase of GC IR in the advanced age, which was more apparent at age ≥50 years (IR 17.16 for 50-59; IR 23.05 for 60-69; and IR 31.62 for ≥70, respectively), contributing to the lower risk of GC in the CKD women than that in the non-CKD women. There was no difference of BC incidence between women with and without CKD.The findings of the lower risk of GCs in the CKD women in Taiwan are worthy of further evaluation.
Conflict of interest statement
The corresponding authors have the right to grant and do grant on behalf of all authors a worldwide license to the Publishers and its licensees in perpetuity. The authors have no funding and conflicts of interest to disclose.
The authors report no conflicts of interest.
Figures
Similar articles
-
Endometriosis Might Be Inversely Associated with Developing Chronic Kidney Disease: A Population-Based Cohort Study in Taiwan.Int J Mol Sci. 2016 Jul 7;17(7):1079. doi: 10.3390/ijms17071079. Int J Mol Sci. 2016. PMID: 27399682 Free PMC article.
-
Impact of Chronic Kidney Disease on Aortic Dissection in Patients with Polycystic Kidney Disease: A Fifteen-year Nationwide Population-based Cohort Study in Taiwan.Int J Med Sci. 2025 Feb 26;22(7):1493-1503. doi: 10.7150/ijms.106518. eCollection 2025. Int J Med Sci. 2025. PMID: 40093803 Free PMC article.
-
Gynecological malignancy risk in colorectal cancer survivors: A population-based cohort study.Eur J Oncol Nurs. 2015 Oct;19(5):473-8. doi: 10.1016/j.ejon.2015.02.006. Epub 2015 Mar 16. Eur J Oncol Nurs. 2015. PMID: 25790918
-
The risk of chronic kidney disease in tuberculosis: a population-based cohort study.QJM. 2015 May;108(5):397-403. doi: 10.1093/qjmed/hcu220. Epub 2014 Oct 28. QJM. 2015. PMID: 25352683
-
The Relationship Between Breast and Gynecological Cancers and a Diagnosis of Serious Mental Illness: A Scoping Review.Nurs Health Sci. 2025 Mar;27(1):e70043. doi: 10.1111/nhs.70043. Nurs Health Sci. 2025. PMID: 39900349
Cited by
-
The association of the decline in glomerular filtration rate with aggressive endometrial cancers.Int Urol Nephrol. 2020 Jan;52(1):161-168. doi: 10.1007/s11255-019-02324-w. Epub 2019 Nov 1. Int Urol Nephrol. 2020. PMID: 31677054
-
Comparing Paclitaxel-Carboplatin with Paclitaxel-Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer.Int J Environ Res Public Health. 2020 Mar 26;17(7):2213. doi: 10.3390/ijerph17072213. Int J Environ Res Public Health. 2020. PMID: 32224896 Free PMC article. Clinical Trial.
-
CAV2 promotes the growth of renal cell carcinoma through the EGFR/PI3K/Akt pathway.Onco Targets Ther. 2018 Sep 25;11:6209-6216. doi: 10.2147/OTT.S172803. eCollection 2018. Onco Targets Ther. 2018. PMID: 30288056 Free PMC article.
-
Weekly Dose-Dense Paclitaxel and Triweekly Low-Dose Cisplatin: A Well-Tolerated and Effective Chemotherapeutic Regimen for First-Line Treatment of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.Int J Environ Res Public Health. 2019 Nov 29;16(23):4794. doi: 10.3390/ijerph16234794. Int J Environ Res Public Health. 2019. PMID: 31795359 Free PMC article.
References
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7–30. - PubMed
-
- Wang PH, Yen MS, Chao KC, et al. Outstanding female cancer research paper awards of the 2015 Taiwan Association of Obstetrics and Gynecology and Hsu Chien-Tien Cancer Foundation. Taiwan J Obstet Gynecol 2016;55:757–9. - PubMed
-
- Wang PH, Chen CP, Kuo TC. Outstanding female cancer research paper awards of the 2016 Taiwanese Association of Obstetrics and Gynecology and Hsu Chien Cancer Foundation. Taiwan J Obstet Gynecol 2017;56:581–2. - PubMed
-
- Wang PH, Chen CP, Kuo TC. Outstanding female cancer research paper awards of the Taiwanese Association of Obstetrics and Gynecology. Taiwan J Obstet Gynecol 2018;57:179–80. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous